Dashboard
Manage Tickers

NVCRNovoCure Ltd

Nasdaq novocure.com


$ 12.64 $ 0.40 (3.31 %)    

Friday, 26-Apr-2024 15:59:55 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 12.635
$ 12.41
$ 0.00 x 0
$ 0.00 x 0
$ 12.36 - $ 12.64
$ 10.87 - $ 83.60
762,109
na
1.34B
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-22-2024 12-31-2023 10-K
2 10-26-2023 09-30-2023 10-Q
3 07-27-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-23-2023 12-31-2022 10-K
6 10-27-2022 09-30-2022 10-Q
7 07-28-2022 06-30-2022 10-Q
8 04-28-2022 03-31-2022 10-Q
9 02-24-2022 12-31-2021 10-K
10 10-28-2021 09-30-2021 10-Q
11 07-29-2021 06-30-2021 10-Q
12 04-29-2021 03-31-2021 10-Q
13 02-25-2021 12-31-2020 10-K
14 10-29-2020 09-30-2020 10-Q
15 07-30-2020 06-30-2020 10-Q
16 04-30-2020 03-31-2020 10-Q
17 02-27-2020 12-31-2019 10-K
18 10-31-2019 09-30-2019 10-Q
19 07-25-2019 06-30-2019 10-Q
20 05-02-2019 03-31-2019 10-Q
21 02-28-2019 12-31-2018 10-K
22 10-25-2018 09-30-2018 10-Q
23 07-26-2018 06-30-2018 10-Q
24 04-26-2018 03-31-2018 10-Q
25 02-22-2018 12-31-2017 10-K
26 10-26-2017 09-30-2017 10-Q
27 07-27-2017 06-30-2017 10-Q
28 04-27-2017 03-31-2017 10-Q
29 02-23-2017 12-31-2016 10-K
30 11-02-2016 09-30-2016 10-Q
31 07-28-2016 06-30-2016 10-Q
32 05-10-2016 03-31-2016 10-Q
33 03-01-2016 12-31-2015 10-K
34 10-27-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

results-of-novocures-metis-phase-3-clinical-trial-for-patients-with-brain-metastasis-from-non-small-cell-lung-cancer-to-be-presented-as-late-breaking-abstract-at-asco-2024
Results Of Novocure's METIS Phase 3 Clinic...
04/24/2024 14:46:57

Novocure (NASDAQ:NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell ...

piper-sandler-reiterates-overweight-on-novocure-raises-price-target-to-28
Piper Sandler Reiterates Overweight on Nov...
04/10/2024 12:55:11

Piper Sandler analyst Jason Bednar reiterates NovoCure (NASDAQ:NVCR) with a Overweight and raises the price target from $25 ...

novocure-reports-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-aacr-annual-meeting-2024
Novocure Reports 20 Presentations On Tumor...
04/05/2024 11:01:17

10-health-care-stocks-whale-activity-in-todays-session
10 Health Care Stocks Whale Activity In To...
04/03/2024 17:35:24

wells-fargo-maintains-overweight-on-novocure-lowers-price-target-to-42
Wells Fargo Maintains Overweight on NovoCu...
04/03/2024 16:43:45

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Overweight and lowers the price target from $49 ...

peeling-back-the-layers-exploring-novocure-through-analyst-insights
Peeling Back The Layers: Exploring NovoCur...
03/27/2024 20:01:01

hc-wainwright--co-maintains-neutral-on-novocure-raises-price-target-to-24
HC Wainwright & Co. Maintains Neutral on N...
03/27/2024 17:44:29

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target fro...

novocure-stock-soars-its-lung-cancer-electric-field-treatment-slows-progression-to-brain-data-shows
Novocure Stock Soars, Its Lung Cancer Elec...
03/27/2024 14:16:57

Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to int...

cintas-reports-upbeat-earnings-joins-paysign-noah-holdings-and-other-big-stocks-moving-higher-on-wednesday
Cintas Reports Upbeat Earnings, Joins PayS...
03/27/2024 14:03:27

U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.

novocure-shares-halted-on-circuit-breaker-to-the-downside-stock-now-up-176
NovoCure Shares Halted On Circuit Breaker ...
03/27/2024 13:37:49

Core News & Articles
Novocure Announces METIS Phase 3 Clinical ...
03/27/2024 13:30:21

The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Field...

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
03/27/2024 13:05:57

Core News & Articles
Market-Moving News for March 27th
03/27/2024 12:31:22

IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for ob...

novocures-metis-phase-3-trial-met-primary-endpoint-demonstrating-statistically-significant-extension-in-time-to-intracranial-progression-for-brain-metastases-from-non-small-cell-lung-cancer
Novocure's METIS Phase 3 Trial Met Primary...
03/27/2024 11:09:25

hc-wainwright--co-reiterates-neutral-on-novocure-maintains-22-price-target
HC Wainwright & Co. Reiterates Neutral on ...
03/12/2024 14:23:43

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $22 price target.

novocure-announced-a-late-breaking-abstract-that-reviews-the-results-of-an-exploratory-subgroup-analysis-of-the-phase-3-engot-ov50gog-3029innovate-3-trial-has-been-selected-at-the-european-society-on-gynecological-oncology-2024-congress
Novocure Announced A Late Breaking Abstrac...
03/11/2024 11:15:58

Exploratory subgroup analysis from INNOVATE-3 finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to re...

why-helix-energy-solutions-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session
Why Helix Energy Solutions Shares Are Trad...
02/27/2024 18:18:56

Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.

hc-wainwright--co-maintains-buy-on-novocure-raises-price-target-to-22
HC Wainwright & Co. Maintains Buy on NovoC...
02/22/2024 19:24:21

HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $2...

novocure-limited-shares-halted-on-circuit-breaker-to-the-downside-stock-now-up-019
NovoCure Limited Shares Halted On Circuit ...
02/22/2024 14:34:56

novocure-q4-eps-045-beats-052-estimate-sales-13378m-beat-13119m-estimate
NovoCure Q4 EPS $(0.45) Beats $(0.52) Esti...
02/22/2024 12:03:56

NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.52) by 1...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION